Download PDF
Planta Med 2014; 80(01): 77-85
DOI: 10.1055/s-0033-1360180
Biological and Pharmacological Activity
Original Papers
Georg Thieme Verlag KG Stuttgart · New York

Inhibition of Tau Aggregation by Three Aspergillus nidulans Secondary Metabolites: 2,ω-Dihydroxyemodin, Asperthecin, and Asperbenzaldehyde

Smita R. Paranjape
1   Department of Molecular Biosciences, University of Kansas, Lawrence, KS, USA
,
Yi-Ming Chiang
2   Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, CA, USA
3   Graduate Institute of Pharmaceutical Science, Chia Nan University School of Pharmacy and Science, Tainan, Taiwan
,
James F. Sanchez
2   Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, CA, USA
,
Ruth Entwistle
1   Department of Molecular Biosciences, University of Kansas, Lawrence, KS, USA
,
Clay C. C. Wang
2   Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, CA, USA
4   Department of Chemistry, Dornsife College of Letters, Arts, and Sciences, University of Southern California, Los Angeles, CA, USA
,
Berl R. Oakley
1   Department of Molecular Biosciences, University of Kansas, Lawrence, KS, USA
,
T. Chris Gamblin
1   Department of Molecular Biosciences, University of Kansas, Lawrence, KS, USA
› Author Affiliations
Further Information

Publication History

received 28 June 2013
revised 25 October 2013

accepted 22 November 2013

Publication Date:
10 January 2014 (online)

Also available at
   Permissions and Reprints

Abstract

The aggregation of the microtubule-associated protein tau is a significant event in many neurodegenerative diseases including Alzheimerʼs disease. The inhibition or reversal of tau aggregation is therefore a potential therapeutic strategy for these diseases. Fungal natural products have proven to be a rich source of useful compounds having wide varieties of biological activity. We have screened Aspergillus nidulans secondary metabolites containing aromatic ring structures for their ability to inhibit tau aggregation in vitro using an arachidonic acid polymerization protocol and the previously identified aggregation inhibitor emodin as a positive control. While several compounds showed some activity, 2,ω-dihydroxyemodin, asperthecin, and asperbenzaldehyde were potent aggregation inhibitors as determined by both a filter trap assay and electron microscopy. In this study, these three compounds were stronger inhibitors than emodin, which has been shown in a prior study to inhibit the heparin induction of tau aggregation with an IC50 of 1–5 µM. Additionally, 2,ω-dihydroxyemodin, asperthecin, and asperbenzaldehyde reduced, but did not block, tau stabilization of microtubules. 2,ω-Dihydroxyemodin and asperthecin have similar structures to previously identified tau aggregation inhibitors, while asperbenzaldehyde represents a new class of compounds with tau aggregation inhibitor activity. Asperbenzaldehyde can be readily modified into compounds with strong lipoxygenase inhibitor activity, suggesting that compounds derived from asperbenzaldehyde could have dual activity. Together, our data demonstrates the potential of 2,ω-dihydroxyemodin, asperthecin, and asperbenzaldehyde as lead compounds for further development as therapeutics to inhibit tau aggregation in Alzheimerʼs disease and neurodegenerative tauopathies.

Key words

tau - microtubule-associated protein - Trichocomaceae - Aspergillus nidulans - Alzheimerʼs disease

Supporting Information

 

  • References

  • 1 Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimerʼs disease. Neurology 1992; 42: 631-639
    CrossrefPubMedGoogle Scholar
  • 2 Goedert M, Crowther RA, Spillantini MG. Tau mutations cause frontotemporal dementias. Neuron 1998; 21: 955-958
    CrossrefPubMedGoogle Scholar
  • 3 Goedert M, Ghetti B, Spillantini MG. Tau gene mutations in frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17). Their relevance for understanding the neurogenerative process. Ann N Y Acad Sci 2000; 920: 74-83
    PubMedGoogle Scholar
  • 4 Ko LW, DeTure M, Sahara N, Chihab R, Vega IE, Yen SH. Recent advances in experimental modeling of the assembly of tau filaments. Biochim Biophys Acta 2005; 1739: 125-139
    CrossrefPubMedGoogle Scholar
  • 5 Brunden KR, Ballatore C, Crowe A, Smith 3rd AB, Lee VM, Trojanowski JQ. Tau-directed drug discovery for Alzheimerʼs disease and related tauopathies: a focus on tau assembly inhibitors. Exp Neurol 2010; 223: 304-310
    CrossrefPubMedGoogle Scholar
  • 6 Martin L, Latypova X, Terro F. Post-translational modifications of tau protein: implications for Alzheimerʼs disease. Neurochem Int 2011; 58: 458-471
    CrossrefPubMedGoogle Scholar
  • 7 Martin L, Latypova X, Wilson CM, Magnaudeix A, Perrin ML, Terro F. Tau protein phosphatases in Alzheimerʼs disease: the leading role of PP2A. Ageing Res Rev 2013; 12: 39-49
    CrossrefPubMedGoogle Scholar
  • 8 Martin L, Latypova X, Wilson CM, Magnaudeix A, Perrin ML, Yardin C, Terro F. Tau protein kinases: involvement in Alzheimerʼs disease. Ageing Res Rev 2013; 12: 289-309
    CrossrefPubMedGoogle Scholar
  • 9 Mondragon-Rodriguez S, Perry G, Luna-Munoz J, Acevedo-Aquino M, Williams S. Phosphorylation of tau protein at sites Ser is one of the earliest events in Alzheimerʼs disease and Down syndrome. Neuropathol Appl Neurobiol 2013; epub ahead of print, DOI: 10.1111/nan.12084. in press
    PubMedGoogle Scholar
  • 10 von Bergen M, Barghorn S, Biernat J, Mandelkow EM, Mandelkow E. Tau aggregation is driven by a transition from random coil to beta sheet structure. Biochim Biophys Acta 2005; 1739: 158-166
    CrossrefPubMedGoogle Scholar
  • 11 von Bergen M, Friedhoff P, Biernat J, Heberle J, Mandelkow E. Assembly of tau protein into Alzheimer paired helical filaments depends on a local sequence motif (306VQIVYK311) forming beta structure. Proc Natl Acad Sci U S A 2000; 97: 5129-5134
    CrossrefPubMedGoogle Scholar
  • 12 Taniguchi S, Suzuki N, Masuda M, Hisanaga S, Iwatsubo T, Goedert M, Hasegawa M. Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins. J Biol Chem 2005; 280: 7614-7623
    CrossrefPubMedGoogle Scholar
  • 13 Wischik CM, Edwards PC, Lai RY, Roth M, Harrington CR. Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proc Natl Acad Sci USA 1996; 93: 11213-11218
    CrossrefPubMedGoogle Scholar
  • 14 Chirita C, Necula M, Kuret J. Ligand-dependent inhibition and reversal of tau filament formation. Biochemistry 2004; 43: 2879-2887
    CrossrefPubMedGoogle Scholar
  • 15 Necula M, Chirita CN, Kuret J. Cyanine dye N744 inhibits tau fibrillization by blocking filament extension: implications for the treatment of tauopathic neurodegenerative diseases. Biochemistry 2005; 44: 10227-10237
    CrossrefPubMedGoogle Scholar
  • 16 Pickhardt M, Gazova Z, von Bergen M, Khlistunova I, Wang Y, Hascher A, Mandelkow EM, Biernat J, Mandelkow E. Anthraquinones inhibit tau aggregation and dissolve Alzheimerʼs paired helical filaments in vitro and in cells. J Biol Chem 2005; 280: 3628-3635
    CrossrefPubMedGoogle Scholar
  • 17 Khlistunova I, Biernat J, Wang Y, Pickhardt M, von Bergen M, Gazova Z, Mandelkow E, Mandelkow EM. Inducible expression of Tau repeat domain in cell models of tauopathy: aggregation is toxic to cells but can be reversed by inhibitor drugs. J Biol Chem 2006; 281: 1205-1214
    CrossrefPubMedGoogle Scholar
  • 18 Pickhardt M, Larbig G, Khlistunova I, Coksezen A, Meyer B, Mandelkow EM, Schmidt B, Mandelkow E. Phenylthiazolyl-hydrazide and its derivatives are potent inhibitors of tau aggregation and toxicity in vitro and in cells. Biochemistry 2007; 46: 10016-10023
    CrossrefPubMedGoogle Scholar
  • 19 Bulic B, Pickhardt M, Khlistunova I, Biernat J, Mandelkow EM, Mandelkow E, Waldmann H. Rhodanine-based tau aggregation inhibitors in cell models of tauopathy. Angew Chem Int Ed Engl 2007; 46: 9215-9219
    CrossrefPubMedGoogle Scholar
  • 20 Crowe A, Ballatore C, Hyde E, Trojanowski JQ, Lee VM. High throughput screening for small molecule inhibitors of heparin-induced tau fibril formation. Biochem Biophys Res Commun 2007; 358: 1-6
    CrossrefPubMedGoogle Scholar
  • 21 Crowe A, Huang W, Ballatore C, Johnson RL, Hogan AM, Huang R, Wichterman J, McCoy J, Huryn D, Auld DS, Smith 3rd AB, Inglese J, Trojanowski JQ, Austin CP, Brunden KR, Lee VM. Identification of aminothienopyridazine inhibitors of tau assembly by quantitative high-throughput screening. Biochemistry 2009; 48: 7732-7745
    CrossrefPubMedGoogle Scholar
  • 22 Oakley CE, Edgerton-Morgan H, Oakley BR. Tools for manipulation of secondary metabolism pathways: rapid promoter replacements and gene deletions in Aspergillus nidulans . Methods Mol Biol 2012; 944: 143-161
    PubMedGoogle Scholar
  • 23 Szewczyk E, Nayak T, Oakley CE, Edgerton H, Xiong Y, Taheri-Talesh N, Osmani SA, Oakley BR. Fusion PCR and gene targeting in Aspergillus nidulans . Nat Protoc 2006; 1: 3111-3120
    PubMedGoogle Scholar
  • 24 Nayak T, Szewczyk E, Oakley CE, Osmani A, Ukil L, Murray SL, Hynes MJ, Osmani SA, Oakley BR. A versatile and efficient gene-targeting system for Aspergillus nidulans . Genetics 2006; 172: 1557-1566
    PubMedGoogle Scholar
  • 25 Soukup AA, Chiang YM, Bok JW, Reyes-Dominguez Y, Oakley BR, Wang CC, Strauss J, Keller NP. Overexpression of the Aspergillus nidulans histone 4 acetyltransferase EsaA increases activation of secondary metabolite production. Mol Microbiol 2012; 86: 314-330
    CrossrefPubMedGoogle Scholar
  • 26 Yeh HH, Chiang YM, Entwistle R, Ahuja M, Lee KH, Bruno KS, Wu TK, Oakley BR, Wang CC. Molecular genetic analysis reveals that a nonribosomal peptide synthetase-like (NRPS-like) gene in Aspergillus nidulans is responsible for microperfuranone biosynthesis. Appl Microbiol Biotechnol 2012; 96: 739-748
    CrossrefPubMedGoogle Scholar
  • 27 Lo HC, Entwistle R, Guo CJ, Ahuja M, Szewczyk E, Hung JH, Chiang YM, Oakley BR, Wang CC. Two separate gene clusters encode the biosynthetic pathway for the meroterpenoids austinol and dehydroaustinol in Aspergillus nidulans . J Am Chem Soc 2012; 134: 4709-4720
    CrossrefPubMedGoogle Scholar
  • 28 Somoza AD, Lee KH, Chiang YM, Oakley BR, Wang CC. Reengineering an azaphilone biosynthesis pathway in Aspergillus nidulans to create lipoxygenase inhibitors. Org Lett 2012; 14: 972-975
    CrossrefPubMedGoogle Scholar
  • 29 Sanchez JF, Entwistle R, Hung JH, Yaegashi J, Jain S, Chiang YM, Wang CC, Oakley BR. Genome-based deletion analysis reveals the prenyl xanthone biosynthesis pathway in Aspergillus nidulans . J Am Chem Soc 2011; 133: 4010-4017
    CrossrefPubMedGoogle Scholar
  • 30 Sanchez JF, Chiang YM, Szewczyk E, Davidson AD, Ahuja M, Elizabeth Oakley C, Woo Bok J, Keller N, Oakley BR, Wang CC. Molecular genetic analysis of the orsellinic acid/F9775 gene cluster of Aspergillus nidulans . Mol Biosyst 2010; 6: 587-593
    CrossrefPubMedGoogle Scholar
  • 31 Chiang YM, Szewczyk E, Davidson AD, Entwistle R, Keller NP, Wang CC, Oakley BR. Characterization of the Aspergillus nidulans monodictyphenone gene cluster. Appl Environ Microbiol 2010; 76: 2067-2074
    CrossrefPubMedGoogle Scholar
  • 32 Chiang YM, Szewczyk E, Davidson AD, Keller N, Oakley BR, Wang CC. A gene cluster containing two fungal polyketide synthases encodes the biosynthetic pathway for a polyketide, asperfuranone, in Aspergillus nidulans . J Am Chem Soc 2009; 131: 2965-2970
    CrossrefPubMedGoogle Scholar
  • 33 Szewczyk E, Chiang YM, Oakley CE, Davidson AD, Wang CC, Oakley BR. Identification and characterization of the asperthecin gene cluster of Aspergillus nidulans . Appl Environ Microbiol 2008; 74: 7607-7612
    CrossrefPubMedGoogle Scholar
  • 34 Chiang YM, Szewczyk E, Nayak T, Davidson AD, Sanchez JF, Lo HC, Ho WY, Simityan H, Kuo E, Praseuth A, Watanabe K, Oakley BR, Wang CC. Molecular genetic mining of the Aspergillus secondary metabolome: discovery of the emericellamide biosynthetic pathway. Chem Biol 2008; 15: 527-532
    CrossrefPubMedGoogle Scholar
  • 35 Carlson SW, Branden M, Voss K, Sun Q, Rankin CA, Gamblin TC. A complex mechanism for inducer mediated tau polymerization. Biochemistry 2007; 46: 8838-8849
    CrossrefPubMedGoogle Scholar
  • 36 Chang E, Kuret J. Detection and quantification of tau aggregation using a membrane filter assay. Anal Biochem 2008; 373: 330-336
    CrossrefPubMedGoogle Scholar
  • 37 Combs B, Gamblin TC. FTDP-17 tau mutations induce distinct effects on aggregation and microtubule interactions. Biochemistry 2012; 51: 8597-8607
    CrossrefPubMedGoogle Scholar
  • 38 King ME, Gamblin TC, Kuret J, Binder LI. Differential assembly of human tau isoforms in the presence of arachidonic acid. J Neurochem 2000; 74: 1749-1757
    PubMedGoogle Scholar
  • 39 Barron DM, Chatterjee SK, Ravindra R, Roof R, Baloglu E, Kingston DG, Bane S. A fluorescence-based high-throughput assay for antimicrotubule drugs. Anal Biochem 2003; 315: 49-56
    CrossrefPubMedGoogle Scholar
  • 40 Necula M, Kuret J. Electron microscopy as a quantitative method for investigating tau fibrillization. Anal Biochem 2004; 329: 238-246
    CrossrefPubMedGoogle Scholar
  • 41 Keller NP, Turner G, Bennett JW. Fungal secondary metabolism – from biochemistry to genomics. Nat Rev Microbiol 2005; 3: 937-947
    CrossrefPubMedGoogle Scholar
  • 42 Sanchez JF, Somoza AD, Keller NP, Wang CC. Advances in Aspergillus secondary metabolite research in the post-genomic era. Nat Prod Rep 2012; 29: 351-371
    CrossrefPubMedGoogle Scholar
  • 43 Combs B, Voss K, Gamblin TC. Pseudohyperphosphorylation has differential effects on polymerization and function of tau isoforms. Biochemistry 2011; 50: 9446-9456
    CrossrefPubMedGoogle Scholar
  • 44 Osmanova N, Schultze W, Ayoub N. Azaphilones: a class of fungal metabolites with diverse biological activities. Phytochem Rev 2010; 9: 315-342
    CrossrefPubMedGoogle Scholar
  • 45 Chu J, Pratico D. Pharmacologic blockade of 5-lipoxygenase improves the amyloidotic phenotype of an Alzheimerʼs disease transgenic mouse model involvement of gamma-secretase. Am J Pathol 2011; 178: 1762-1769
    CrossrefPubMedGoogle Scholar
  • 46 Rankin CA, Sun Q, Gamblin TC. Pseudo-phosphorylation of tau at Ser202 and Thr205 affects tau filament formation. Brain Res Mol Brain Res 2005; 138: 84-93
    CrossrefPubMedGoogle Scholar
  • 47 Ahuja M, Chiang YM, Chang SL, Praseuth MB, Entwistle R, Sanchez JF, Lo HC, Yeh HH, Oakley BR, Wang CC. Illuminating the diversity of aromatic polyketide synthases in Aspergillus nidulans . J Am Chem Soc 2012; 134: 8212-8221
    CrossrefPubMedGoogle Scholar
  • 48 Bok JW, Chiang YM, Szewczyk E, Reyes-Dominguez Y, Davidson AD, Sanchez JF, Lo HC, Watanabe K, Strauss J, Oakley BR, Wang CC, Keller NP. Chromatin-level regulation of biosynthetic gene clusters. Nat Chem Biol 2009; 5: 462-464
    CrossrefPubMedGoogle Scholar
  • 49 LoPresti P, Szuchet S, Papasozomenos SC, Zinkowski RP, Binder LI. Functional implications for the microtubule-associated protein tau: localization in oligodendrocytes. Proc Natl Acad Sci USA 1995; 92: 10369-10373
    CrossrefPubMedGoogle Scholar
  • 50 Horowitz PM, Patterson KR, Guillozet-Bongaarts AL, Reynolds MR, Carroll CA, Weintraub ST, Bennett DA, Cryns VL, Berry RW, Binder LI. Early N-terminal changes and caspase-6 cleavage of tau in Alzheimerʼs disease. J Neurosci 2004; 24: 7895-7902
    CrossrefPubMedGoogle Scholar
  • 51 Horowitz PM, Lapointe N, Guillozet-Bongaarts AL, Berry RW, Binder LI. N-terminal fragments of tau inhibit full-length tau polymerization in vitro . Biochemistry 2006; 45: 12859-12866
    CrossrefPubMedGoogle Scholar